URMC Vaccine and Treatment Evaluation Unit

The University of Rochester Medical Center will resume the clinical trial of a potential coronavirus vaccine after it was halted in early September.

The trial of the vaccine, developed by pharmaceutical company AstraZeneca, was stopped after one British participant developed severe neurological symptoms consistent with a rare inflammation of the spinal cord.

Recently, the drug maker got the go-ahead from the U.S. Food and Drug Administration to restart tests in the U.S.

The University of Rochester Medical Center is conducting another Phase 3 clinical trial for a potential coronavirus vaccine under the federal Operation Warp Speed initiative.

More than 30,000 people from around the country will be recruited for the study, including 1,000 in Rochester. Volunteers will receive the first doses of the vaccine, which was developed by AstraZeneca and the University of Oxford.